Zoetis Inc. announced that the European Commission (EC) has granted marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine designed to protect chickens against Newcastle disease and Marek’s disease viruses. The authorization allows for the vaccine's use in commercial poultry operations, addressing significant mortality and production losses caused by these diseases. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both pathogens with a single dose.

Newcastle disease is classified as a notifiable disease under EU animal health regulations. Recent confirmed outbreaks in Germany, Spain, and Poland have highlighted its impact on commercial poultry. The vaccine utilizes the herpesvirus of turkey (HVT) as its vector, an avirulent virus capable of replicating in chickens that has served as a vaccine vector in poultry for approximately two decades.

Vaccine Mechanism

Poulvac Procerta HVT-ND functions by expressing a Newcastle disease virus antigen. This expression stimulates immunity against Newcastle disease while simultaneously delivering protection against Marek’s disease. The dual-action capability reduces the need for multiple vaccinations, streamlining the immunization process for poultry producers.

Key Features

HSBC analyst Rajesh Kumar has maintained a Buy rating on Zoetis (NYSE: ZTS) while lowering the price target to $95 from the previous $140. The revised target suggests a reassessment of the company's valuation or growth prospects, despite the continued positive stance on the stock.

Rating and Price Target Details

The decision to maintain a Buy rating indicates that the stock is expected to outperform the broader market. The reduction in the price target signals a more tempered outlook on the stock's near-term performance.

Zoetis continues to be monitored for its operational performance and market conditions. The new price target provides a reference point for investors considering the stock's potential trajectory.